AP-505
- Generic Name
- AP-505
A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06838546
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hanzhou, Hanzhou, China
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AP Biosciences Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06723964
- Locations
- 🇨🇳
AP Biosciences, Inc., Taipei, Taiwan
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian CancerTriple Negative Breast Cancer (TNBC)Cervical CancersSmall Cell Lung CancerHepatocellular Carcinoma (HCC)Colorectal CancerNon-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06724263
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05650385
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath